Drug profile

The FDA adverse-event record for Canine Adenovirus Type 2, Manhattan, Mlv; Canine Distemper Virus, N-Cdv, Mlv; Ca

36 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Canine Adenovirus Type 2, Manhattan, Mlv; Canine Distemper Virus, N-Cdv, Mlv; Ca. See the species affected, top reactions, and outcomes below.

36
adverse-event reports
13.9%
death-coded share
Dog
most-reported species
15
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
36
Total Reports
5
Deaths Reported
13.9%
Death Rate

Active Ingredients

Canine Adenovirus Type 2, Manhattan, Mlv; Canine Distemper Virus, N-Cdv, Mlv; Ca

Administration Routes

Subcutaneous

Species Affected

Dog 36

Most Affected Breeds

Retriever - Labrador 5
Chihuahua 4
Terrier - Bull - American Pit 4
Crossbred Canine/dog 3
Boxer (German Boxer) 2
Siberian Husky 2
Saint Bernard Dog 2
Terrier - Yorkshire 1
Shepherd (unspecified) 1
Spitz - German Pomeranian 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 15
Vomiting 11
Anaphylactoid reaction 8
Other abnormal test result NOS 6
Elevated liver enzymes 5
Facial swelling (see also 'Skin') 5
Anaphylaxis 4
Anaemia NOS 4
Emesis 4
Anorexia 4
Diarrhoea 4
INEFFECTIVE, ANTIEMETIC 4

Outcome Breakdown

Ongoing
19 (52.8%)
Recovered/Normal
9 (25.0%)
Died
3 (8.3%)
Euthanized
2 (5.6%)
Outcome Unknown
2 (5.6%)
Recovered with Sequela
1 (2.8%)

Canine Adenovirus Type 2, Manhattan, Mlv; Canine Distemper Virus, N-Cdv, Mlv; Ca Adverse Event Insights

36 reports name Canine Adenovirus Type 2, Manhattan, Mlv; Canine Distemper Virus, N-Cdv, Mlv; Ca; 5 recorded a death outcome (13.9% of reported events, not a population-level mortality rate). Active ingredient: Canine Adenovirus Type 2, Manhattan, Mlv; Canine Distemper Virus, N-Cdv, Mlv; Ca. Administration route: Subcutaneous.

By species: Dog (36 reports). By breed: Retriever - Labrador (5), Chihuahua (4), Terrier - Bull - American Pit (4).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (15), Vomiting (11), Anaphylactoid reaction (8), Other abnormal test result NOS (6). Outcome, 36 coded reports: Ongoing leads at 52.8%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.